Summary & Overview
HCPCS J1737: Meloxicam (azurity) Injection, 1 mg
HCPCS Level II code J1737 denotes a 1 mg injection of meloxicam (azurity), a parenteral nonsteroidal anti-inflammatory used for analgesia and inflammation control. As an HCPCS Level II drug code, J1737 is used on professional and facility claims to report administration of the product and is relevant to billing for outpatient infusion clinics, ambulatory surgical centers, and hospital outpatient departments. Nationally, accurate reporting of this code affects payment, utilization tracking, and formulary management for injectable NSAID therapy.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmarking context on payer coverage patterns and reimbursement treatment, a summary of clinical use and service settings, and relevant coding considerations for claims submission. The publication outlines common billing scenarios, expected places of service, and where to look for payer-specific policies and prior authorization requirements.
This summary is intended to provide clinicians, billing professionals, and policy analysts with a concise reference to HCPCS Level II code J1737, its clinical role, and the payer landscape that influences access and payment for injectable meloxicam.
Billing Code Overview
HCPCS Level II code J1737 describes an injection of meloxicam (azurity), 1 mg. This code represents a single unit of the parenteral formulation of meloxicam intended for administration by a clinician.
Service type: Injectable non-opioid analgesic/anti-inflammatory medication
Typical site of service: Outpatient infusion or clinic setting, ambulatory surgical center, or hospital outpatient department
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with chronic osteoarthritis of the knee or shoulder who has inadequate pain control or intolerance to oral NSAIDs and is scheduled to receive an in-clinic intramuscular or subcutaneous injection of extended‑release meloxicam, billed as J1737 (injection, meloxicam (azurity), 1 mg). The clinical workflow begins with a physician or advanced practice provider evaluation documenting diagnosis, pain severity, prior therapies tried, and informed consent for an injectable NSAID. Nursing staff verify allergies, obtain baseline vitals, and prepare the appropriate dose by drawing the required milligrams from the supplied vial or prefilled syringe. The injection is administered in an ambulatory clinic, outpatient infusion center, or physician office by a licensed nurse or clinician. Post‑administration monitoring for 15–30 minutes assesses for acute hypersensitivity, hemodynamic stability, and local injection site reaction before discharge. Medication administration, lot number, and site of injection are documented in the medical record. Subsequent follow‑up visits evaluate efficacy, adverse effects, renal function, and need for repeat dosing according to the product labeling and payer policies.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, Separately Identifiable Evaluation and Management Service by the Same Physician on the Same Day of the Procedure | Use when a separate E/M visit is documented on the same day as and the E/M meets all criteria. |